I Paid $300 for DNA-based fitness advice and all I got was junk science
By Angela Chen,
The Verge
| 11. 20. 2017
In January of this year, I decided I would complete a half-marathon. I would push my body to the limit and be reborn as my best self. For months, I woke up at 6 to run before work, motivated by the promise of sweet endorphins and even-sweeter self-righteousness. But then the winter wore on, and I gained some weight, and now I’m back to 5Ks instead.
In my quest to return to former glory, I redownloaded the “couch to half-marathon” app and spent $100 on a pair of New Balance shoes. I became interested in a genetic-testing kit that promised to provide the information I needed to complete 13.1 miles once and for all.
Genetic testing for wellness seems like a natural choice for someone like me. I still wear my Fitbit every day two years after getting it, making me one of the few and the proud that have stuck with their device for longer than six months. I own a smart scale and a running watch; I track calories and read training forums. But the forum...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...